Hofseth BioCare ASA (FRA:HBQ)
Germany · Delayed Price · Currency is EUR 0.0816
-0.0092 (-10.13%)
At close: Jan 23, 2026
Hofseth BioCare ASA Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 248.21 | 256.83 | 190.82 | 119.13 | 76.88 | 52.51 |
Other Revenue | 0.86 | 8.71 | 27.7 | 1.32 | 10.74 | 16.74 |
| 249.08 | 265.54 | 218.51 | 120.45 | 87.62 | 69.25 | |
Revenue Growth (YoY) | 0.40% | 21.52% | 81.42% | 37.47% | 26.52% | 2.17% |
Cost of Revenue | 174.38 | 189.81 | 165 | 102.49 | 77.05 | 39.53 |
Gross Profit | 74.7 | 75.73 | 53.51 | 17.96 | 10.57 | 29.72 |
Selling, General & Admin | 98.83 | 91.37 | 76.25 | 76.03 | 60.35 | 42.64 |
Other Operating Expenses | 48.32 | 49.66 | 43.38 | 40.13 | 39.43 | 52.33 |
Operating Expenses | 186.36 | 180.81 | 156.04 | 146.39 | 129.13 | 121.74 |
Operating Income | -111.67 | -105.08 | -102.53 | -128.43 | -118.56 | -92.02 |
Interest Expense | -20.63 | -15.69 | -7.54 | -9.95 | -9.39 | -9.22 |
Interest & Investment Income | 1.84 | 0.79 | 0.55 | 0.65 | 0.61 | 0.55 |
Earnings From Equity Investments | 1.7 | -7.48 | 2.54 | -0.2 | 0.03 | -0.78 |
Currency Exchange Gain (Loss) | -1.34 | 2.16 | 0.3 | 0.74 | 0.91 | -0.54 |
Other Non Operating Income (Expenses) | -0.05 | - | -0 | - | -0.06 | -0.09 |
EBT Excluding Unusual Items | -130.15 | -125.3 | -106.69 | -137.2 | -126.46 | -102.09 |
Asset Writedown | - | - | - | -0.19 | - | - |
Pretax Income | -130.15 | -125.3 | -106.69 | -137.39 | -126.46 | -102.09 |
Income Tax Expense | 0.18 | - | - | - | - | - |
Earnings From Continuing Operations | -130.32 | -125.3 | -106.69 | -137.39 | -126.46 | -102.09 |
Minority Interest in Earnings | 0 | 0 | 0 | 0 | 0 | 0 |
Net Income | -130.32 | -125.3 | -106.68 | -137.39 | -126.46 | -102.09 |
Net Income to Common | -130.32 | -125.3 | -106.68 | -137.39 | -126.46 | -102.09 |
Shares Outstanding (Basic) | 411 | 411 | 395 | 375 | 358 | 334 |
Shares Outstanding (Diluted) | 411 | 411 | 395 | 375 | 358 | 334 |
Shares Change (YoY) | 1.03% | 4.01% | 5.43% | 4.72% | 7.25% | 8.96% |
EPS (Basic) | -0.32 | -0.30 | -0.27 | -0.37 | -0.35 | -0.31 |
EPS (Diluted) | -0.32 | -0.30 | -0.27 | -0.37 | -0.35 | -0.31 |
Free Cash Flow | -31.37 | -12.22 | -5.43 | -49.19 | -84.7 | -94.21 |
Free Cash Flow Per Share | -0.08 | -0.03 | -0.01 | -0.13 | -0.24 | -0.28 |
Gross Margin | 29.99% | 28.52% | 24.49% | 14.91% | 12.06% | 42.92% |
Operating Margin | -44.83% | -39.57% | -46.92% | -106.63% | -135.32% | -132.88% |
Profit Margin | -52.32% | -47.19% | -48.82% | -114.06% | -144.34% | -147.42% |
Free Cash Flow Margin | -12.60% | -4.60% | -2.49% | -40.84% | -96.67% | -136.03% |
EBITDA | -97.86 | -90.71 | -89.83 | -118.46 | -104.57 | -79 |
EBITDA Margin | -39.29% | -34.16% | -41.11% | -98.35% | -119.35% | -114.08% |
D&A For EBITDA | 13.81 | 14.37 | 12.7 | 9.97 | 14 | 13.02 |
EBIT | -111.67 | -105.08 | -102.53 | -128.43 | -118.56 | -92.02 |
EBIT Margin | -44.83% | -39.57% | -46.92% | -106.63% | -135.32% | -132.88% |
Revenue as Reported | 249.08 | 265.54 | 218.51 | 120.45 | 87.62 | 69.25 |
Advertising Expenses | - | 15.33 | 13.49 | 15.04 | 13.03 | 7.86 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.